"Moving Forward Together Amid the Pandemic: Digital Collaboration! TrialOS Pharmaceutical R&D Collaboration Platform Empowers China's Medical Innovation"
At the beginning of 2022, the Omicron variant struck, causing the COVID-19 pandemic to once again affect numerous provinces and cities across China. The healthcare system faced renewed challenges, with outpatient and emergency services operating on an irregular basis. Medical staff were fully deployed to the front lines of the epidemic response, and various provinces and municipalities provided mutual aid and support.
During challenging times, clinical trial demands across the entire healthcare system struggle to be prioritized, leading to difficulties in patient recruitment and delays in project initiation. To prevent the risk of infection among subjects, routine visits become difficult to conduct, resulting in significant subject dropout. Logistics disruptions place immense pressure on the targeted distribution of investigational drugs to clinical trial sites. Incomplete data hinders successful regulatory registration. Furthermore, risks such as site closures hang like multiple “Swords of Damocles” over industry practitioners, poised at any moment to bring catastrophic failure to their projects.
In the face of the severe current situation, clinical professionals must remain vigilant. Today’s and future clinical trials must integrate remote, collaborative, digital, online, and intelligent elements as extensively as possible into every stage of the trial process. This ensures that clinical trials can continue uninterrupted in the event of any emergency, thereby facilitating the market approval of effective medicines.
TrialOS, a collaborative platform for pharmaceutical R&D, offers a potential solution to break through the aforementioned challenges.
Since its launch, the TrialOS Pharmaceutical R&D Collaboration Platform has, to adapt to evolving market demands, increasing complexity in clinical trials, heightened regulatory requirements, a changing external environment, and unexpected events, today:
In key clinical operations scenarios, TrialOS ensures close connectivity and smooth operation across all parties and processes during the pandemic through high-level collaboration and optimized resource integration:
● Supports online project initiation for 550 institutions with fully digital application and review processes; facilitates the development of dozens of digital Phase I clinical trial wards.
● Establish a nationwide remote monitoring network to enable online compliance monitoring by Clinical Research Associates (CRAs), thereby reducing or eliminating the need for business travel and on-site work;
● Supports remote clinical trials, remote follow-ups, and doctor-patient communication, reducing offline contact while ensuring patient compliance;
● Integrates over 200 SMO companies to form an SMO collaboration network, enabling sponsors to find partners in one place, conduct online interviews, and quickly match with CRCs; additionally, it adopts a digitalized center-based management model to standardize and streamline CRC workflows, thereby enhancing quality and efficiency.
● Access to a network of 1,600+ imaging interpretation experts, enhancing diagnostic efficiency and accuracy through a digital, independent image interpretation system and fully online workflows;
● Online reporting, multi-party routing, and processing of SAEs/SUSARs improve efficiency while eliminating various offline interactions.
The TrialOS platform integrates over 30 clinical trial SaaS applications, providing a unified login portal that covers the entire clinical trial lifecycle. It supports bioequivalence (BE) studies, Phase I–III trials, as well as post-marketing research such as real-world evidence (RWE) studies and investigator-initiated trials (IITs). Serving all trial stakeholders—including sponsors, investigative sites, and third-party service providers—the platform eliminates the burden of sifting through numerous software options and engaging in costly trial-and-error processes.
The application of digital software not only serves as a critical guarantee for quality, efficiency, compliance, and cost control, but also enables online collaboration among all parties through native data exchange and process integration across software within the same platform. This reduces offline workflows and continues to drive trial progress even during the pandemic.
TrialOS integrates tens of thousands of industry data points and offers nearly 10 knowledge query tools, providing basic information, project details, announcements, and central document downloads for over 10,000 hospitals and more than 1,000 drug clinical trial institutions; names, affiliations, and sponsored trial projects for over 17,000 investigators; and complete public registration information for more than 16,000 publicly disclosed clinical trials. Data can be searched and filtered by dimensions such as sponsor, institution, investigator, indication, and progress status, enabling comprehensive access to industry information in one place. Practical tools including CTCAE v5, TNM staging, abnormality interpretation, and medical translation further support knowledge queries across all stages of clinical trials.
TrialOS has invited hundreds of expert instructors to develop over 1,000 courses on clinical trials, covering more than 20 categories including GCP, project management, clinical operations, data management, statistical analysis, pharmacovigilance, and RWE. With continuously updated and expanding content, as well as three to four free live streaming sessions per week, TrialOS supports the professional knowledge acquisition and personal growth of clinical trial practitioners.
To date, TrialOS has provided digital solutions to over 1,000 pharmaceutical companies/CROs and more than 550 clinical trial institutions. Between 2018 and 2020, it supported the research, development, and market launch of approximately 40% of China’s Class 1 new drugs. Annually, around 20% of adverse drug reaction reports are submitted to the National Center for ADR Monitoring via TrialOS (2020 statistics), and the platform has already interfaced with relevant databases of regulatory authorities in 34 countries/regions.
According to Frost & Sullivan’s report, “Market for Technology Solutions in the Life Sciences Industry,” Taimei Medical Technology holds a leading market share across China for multiple core SaaS products. IDC’s report, “China Life Sciences R&D Information System Market Share, 2019: Emerging IT Technologies Accelerating New Drug Development,” indicates that Taimei Medical Technology ranks first among vendors of life sciences R&D information system solutions in China... TrialOS has become a significant force driving high-quality development in pharmaceutical innovation in China.
Nowadays, the resurgence of the pandemic poses a challenge to the industry and serves as a major test for TrialOS. It also presents another significant opportunity to demonstrate the responsibility of an innovative platform and support pharmaceutical innovation in China!
TrialOS: Detailed Preview to Follow
TrialOS: Digital Collaboration in the Fight Against COVID-19
1. Integrating industry insights and thousands of training courses, clinical professionals are growing every day!
2. App Store: Comprehensive Coverage of Digital Clinical Research Software!
3. Digital Collaboration Safeguards the Smooth Conduct of Clinical Trials, Driving Continuous Innovation!
4. Online workflow for SAE/SUSAR to ensure timely processing!
5. High-volume image reading for clinical trials, completed online to safeguard clinical trial integrity!
6. One-Stop Online Selection of SMOs for Nationwide Multicenter Trials, with Rapid CRC Matching!
